Literature DB >> 15265514

NMR studies of the inclusion complex between beta-cyclodextrin and paroxetine.

Andrea Bernini1, Ottavia Spiga, Arianna Ciutti, Maria Scarselli, Giuseppe Bottoni, Paolo Mascagni, Neri Niccolai.   

Abstract

A 1H and 13C NMR study on the inclusion complex of paroxetine with beta-cyclodextrin was carried out in order to define the stoichiometry of the association and its strength. Proton and carbon chemical shift measurements of paroxetine and beta-cyclodextrin were performed at several molar ratios and temperatures, allowing the determination of a 1:1 stoichiometry and an association constant value of the order of 2 x 10(3) for the paroxetine-beta-cyclodextrin complex. Overhauser effects in the rotating frame were also measured, and the experimental interproton distance constraints have been used for molecular model building of the complex. The obtained model indicates that the benzodioxolyl moiety of paroxetine is deeply inserted in the cavity of the cylindrical structure of beta-cyclodextrin, while the fluoro-phenyl ring lays above the wider rim.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265514     DOI: 10.1016/j.ejps.2004.04.007

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  9 in total

1.  Interaction of omeprazole with a methylated derivative of beta-cyclodextrin: phase solubility, NMR spectroscopy and molecular simulation.

Authors:  Ana Figueiras; J M G Sarraguça; Rui A Carvalho; A A C C Pais; Francisco J B Veiga
Journal:  Pharm Res       Date:  2006-12-20       Impact factor: 4.200

2.  Improved Aqueous Solubility and Antihypercholesterolemic Activity of Ezetimibe on Formulating with Hydroxypropyl-β-Cyclodextrin and Hydrophilic Auxiliary Substances.

Authors:  Kale Mohana Raghava Srivalli; Brahmeshwar Mishra
Journal:  AAPS PharmSciTech       Date:  2015-06-16       Impact factor: 3.246

3.  Inclusion complex of novel curcumin analogue CDF and β-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer.

Authors:  Prasad R Dandawate; Alok Vyas; Aamir Ahmad; Sanjeev Banerjee; Jyoti Deshpande; K Venkateswara Swamy; Abeda Jamadar; Anne Catherine Dumhe-Klaire; Subhash Padhye; Fazlul H Sarkar
Journal:  Pharm Res       Date:  2012-02-10       Impact factor: 4.200

4.  Conventional study on novel dicationic ionic liquid inclusion with β-cyclodextrin.

Authors:  Sharifah Mohamad; Hemavathy Surikumaran; Muggundha Raoov; Tilagam Marimuthu; Kumuthini Chandrasekaram; Puvaneswary Subramaniam
Journal:  Int J Mol Sci       Date:  2011-09-23       Impact factor: 5.923

5.  Pharmaceutical composition of valsartan: beta-cyclodextrin: physico-chemical characterization and anti-hypertensive evaluation.

Authors:  Carlos Eduardo de Matos Jensen; Robson Augusto Souza dos Santos; Angelo Márcio Leite Denadai; Cynthia Fernandes Ferreira Santos; Aline Nardoni Gonçalves Braga; Rubén Dario Sinisterra
Journal:  Molecules       Date:  2010-06-04       Impact factor: 4.411

6.  Encapsulation Mechanism of Oxyresveratrol by β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin and Computational Analysis.

Authors:  Jianfei He; Zong-Ping Zheng; Qin Zhu; Fengxian Guo; Jie Chen
Journal:  Molecules       Date:  2017-10-31       Impact factor: 4.411

7.  Evaluation of the taste-masking effects of (2-hydroxypropyl)-β-cyclodextrin on ranitidine hydrochloride; a combined biosensor, spectroscopic and molecular modelling assessment.

Authors:  Sai Kin Chay; Alison V Keating; Colin James; Abil E Aliev; Shozeb Haider; Duncan Q M Craig
Journal:  RSC Adv       Date:  2018-01-17       Impact factor: 4.036

8.  Mass spectrometry and molecular modeling studies on the inclusion complexes between alendronate and β-cyclodextrin.

Authors:  Joanna Biernacka; Katarzyna Betlejewska-Kielak; Janina Witowska-Jarosz; Ewa Kłosińska-Szmurło; Aleksander P Mazurek
Journal:  J Incl Phenom Macrocycl Chem       Date:  2013-04-17       Impact factor: 1.633

9.  Inclusion Scenarios and Conformational Flexibility of the SSRI Paroxetine as Perceived from Polymorphism of β-Cyclodextrin-Paroxetine Complex.

Authors:  Thammarat Aree
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.